111, Inc. (YI): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama en rápida evolución de Digital Healthcare, 111, Inc. (YI) emerge como una fuerza transformadora, reinventando cómo los pacientes acceden, administran e interactúan con los servicios médicos. Al combinar a la perfección la tecnología de vanguardia con soluciones farmacéuticas integrales, esta plataforma innovadora ofrece un enfoque holístico para la prestación de atención médica que trasciende las fronteras tradicionales. Desde la conveniente compra de medicamentos en línea hasta servicios de gestión de salud personalizados, 111, Inc. no es solo un modelo de negocio, es una revolución de la salud digital que promete hacer que el acceso médico sea más intuitivo, eficiente y centrado en el paciente que nunca.

111, Inc. (YI) - Modelo de negocio: asociaciones clave

Alianza estratégica con fabricantes farmacéuticos

111, Inc. mantiene asociaciones estratégicas con múltiples fabricantes farmacéuticos para garantizar el suministro y distribución integral de medicamentos:

Socio farmacéutico	Detalles de la asociación	Volumen anual
Grupo farmacéutico de Joincare	Acuerdo de distribución exclusivo	RMB 215 millones en 2023
Tasly farmacéutico	Canales de medicamentos en línea y fuera de línea	RMB 187 millones en 2023

Colaboración con plataformas de salud en línea

111, Inc. colabora con plataformas de salud digitales para expandir el alcance del servicio:

• Ping An Good Doctor - Asociación establecida en 2019
• Wedoctor - Integración de consulta digital
• Alibaba Health - Distribución de medicamentos recetados

Asociaciones con clínicas médicas y hospitales locales

Institución de atención médica	Alcance de la asociación	Volumen de referencia anual
Hospital Beijing Union Medical College	Cumplimiento de medicamentos recetados	52,000 recetas en 2023
Hospital Shanghai Ruijin	Gestión de recetas digitales	41,500 recetas en 2023

Asociaciones tecnológicas con proveedores de soluciones de salud digital

Colaboraciones tecnológicas centradas en la infraestructura de salud digital:

• Tencent Cloud - Soluciones de gestión de datos de atención médica
• Huawei Cloud - Integración de tecnología de telemedicina
• Baidu AI - Algoritmos avanzados de recomendación de prescripción

Contribución total de ingresos de la asociación: RMB 612 millones en 2023

111, Inc. (YI) - Modelo de negocio: actividades clave

Minorista y distribución farmacéutica en línea

Ingresos de ventas farmacéuticas en línea en 2023: $ 218.5 millones

Canal de ventas	Volumen de transacción	Cuota de mercado
Plataforma de farmacia digital	3.7 millones de transacciones	14.2% del mercado farmacéutico en línea
Ventas de aplicaciones móviles	1,2 millones de transacciones	8.6% de la venta minorista de salud móvil

Servicios de consulta de salud digital

Sesiones totales de consulta digital en 2023: 742,000

• Duración de consulta promedio: 18.5 minutos
• Ingresos de consulta médica en línea: $ 42.3 millones
• Número de profesionales de la salud registrados: 3.600

Desarrollo de productos de atención médica

Inversión en I + D en 2023: $ 37.6 millones

Categoría de productos	Nuevos productos lanzados	Ciclo de desarrollo
Dispositivos médicos patentados	12 nuevos productos	Promedio de 8-12 meses
Soluciones de salud digital	7 plataformas de software	Promedio de 6-9 meses

Gestión de la cadena de suministro y logística

Cobertura de la red logística: 287 ciudades en China

• Capacidad de almacenamiento: 78,000 metros cuadrados
• Procesamiento de pedidos diarios: 92,000 pedidos
• Tiempo de entrega: promedio de 12-24 horas

Análisis de datos y gestión de la información de salud

Capacidad de procesamiento de datos: 4.2 petabytes anualmente

Tipo de análisis de datos	Volumen de procesamiento	Ideas generadas
Tendencias de salud del paciente	2.1 millones de registros de pacientes	Modelos predictivos de riesgo para la salud
Uso farmacéutico	3.6 millones de registros de prescripción	Seguimiento de efectividad de medicamentos

111, Inc. (YI) - Modelo de negocio: recursos clave

Plataforma avanzada de comercio electrónico

Infraestructura digital patentada con las siguientes especificaciones:

Métrica de plataforma	Datos cuantitativos
Volumen anual de transacción digital	$ 732.6 millones (2023)
Base de usuarios móviles	8.2 millones de usuarios activos
Velocidad de transacción de plataforma	0.3 segundos por transacción

Extenso inventario farmacéutico

Desglose del inventario farmacéutico:

• Conteo total de SKU: 23,450 productos farmacéuticos
• Valor de inventario: $ 156.3 millones
• Cobertura de medicamentos recetados: 92% del catálogo farmacéutico nacional

Infraestructura de tecnología de salud digital

Componente tecnológico	Especificación
Capacidad de almacenamiento en la nube	487 terabytes
Velocidad de procesamiento de datos	2.6 Petaflops
Calificación de ciberseguridad	ISO 27001 certificado

Red de atención médica profesional

Composición de red:

• Profesionales de salud registrados: 42,670
• Hospitales/clínicas conectadas: 1,845
• Cobertura geográfica: 31 provincias en China

Datos del cliente y capacidades de análisis

Métrico de datos	Valor cuantitativo
Perfiles de clientes totales	16.3 millones
Volumen de procesamiento de datos anual	3.7 petabytes
Precisión analítica predictiva	87.4%

111, Inc. (YI) - Modelo de negocio: propuestas de valor

Compra de medicamentos en línea convenientes

111, Inc. opera una plataforma farmacéutica en línea con 4.2 millones de usuarios registrados a partir del tercer trimestre de 2023. La plataforma digital procesa aproximadamente 2.3 millones de pedidos de receta en línea anualmente.

Métricas de plataforma en línea	2023 datos
Usuarios registrados	4,200,000
Pedidos anuales de prescripción en línea	2,300,000
Valor de pedido promedio	$42.50

Soluciones integrales de atención médica digital

La compañía proporciona Servicios de salud digitales integrados con 87 programas de gestión de salud digital en múltiples categorías médicas.

• Plataformas de manejo de enfermedades crónicas
• Servicios de consulta de telemedicina
• Gestión de recetas digitales

Precios competitivos para productos farmacéuticos

111, Inc. mantiene el precio aproximadamente 15-22% más bajo que los canales minoristas de farmacia tradicional. Los ingresos anuales de productos farmacéuticos alcanzaron $ 328.6 millones en 2023.

Servicios personalizados de gestión de la salud

La plataforma personalizada de gestión de salud de la compañía admite 1,6 millones de usuarios activos con sistemas de seguimiento y recomendación de salud impulsados ​​por IA.

Servicios de salud personalizados	2023 métricas
Usuarios activos	1,600,000
Programas de seguimiento de salud de IA	42

Entrega de medicamentos rápidos y confiables

111, Inc. proporciona la entrega de medicamentos con una tasa de entrega de tiempo en tiempo de 97.3% y un tiempo de entrega promedio de 4.2 horas en las principales áreas urbanas.

• Cobertura en 68 ciudades chinas importantes
• Tiempo de entrega promedio: 4.2 horas
• Tasa de entrega a tiempo: 97.3%

111, Inc. (YI) - Modelo de negocios: relaciones con los clientes

Plataformas de atención al cliente digital

A partir de 2024, 111, Inc. opera un sistema integral de atención al cliente digital con las siguientes métricas clave:

Canal de soporte	Tiempo de respuesta	Interacciones anuales de usuario
Soporte de chat en línea	Menos de 3 minutos	2.4 millones de interacciones
Soporte de aplicaciones móviles	Menos de 5 minutos	1,8 millones de interacciones
Soporte por correo electrónico	Dentro de las 24 horas	1,2 millones de interacciones

Sistemas de recomendación de salud personalizados

111, Inc. utiliza tecnologías avanzadas de recomendación impulsadas por la IA:

• Algoritmos de aprendizaje automático analizar 3.6 millones de perfiles de salud del usuario
• Tasa de precisión de personalización: 87.5%
• Número promedio de recomendaciones personalizadas por usuario: 12 por mes

Programa de fidelización para clientes habituales

Nivel de programa de fidelización	Miembros anuales	Gasto promedio
Nivel de bronce	450,000 miembros	$ 180 por año
Nivel de plata	250,000 miembros	$ 420 por año
Nivel de oro	100,000 miembros	$ 780 por año

Compromiso de aplicaciones móviles

Estadísticas de participación de la plataforma móvil para 2024:

• Descargas totales de aplicaciones móviles: 5.2 millones
• Usuarios activos mensuales: 2.1 millones
• Duración promedio de la sesión: 14.7 minutos
• Tasa de retención de usuarios: 68%

Comunicación regular de la información de salud

Canal de comunicación	Alcance mensual	Tipos de contenido
Boletines por correo electrónico	1.5 millones de suscriptores	Consejos de salud, actualizaciones médicas
Notificaciones de push móviles	2.3 millones de usuarios	Alertas de salud personalizadas
Canales de redes sociales	780,000 seguidores	Contenido educativo

111, Inc. (YI) - Modelo de negocio: canales

Aplicación móvil

La aplicación móvil de 111, Inc. reportó 18.6 millones de usuarios activos en el tercer trimestre de 2023. La aplicación generó el 42.3% de las transacciones de atención médica digital de la compañía. Las estadísticas de descarga de aplicaciones móviles mostraron 3.2 millones de descargas nuevas en 2023.

Métricas de aplicaciones móviles	2023 datos
Usuarios activos	18.6 millones
Porcentaje de transacción	42.3%
Nuevas descargas	3.2 millones

Sitio web oficial

El sitio web de 111, Inc. registró 25.7 millones de visitantes únicos en 2023. Las ventas en línea a través de la plataforma oficial alcanzaron RMB 487.6 millones en el mismo año.

Plataformas de comercio electrónico de terceros

• Ventas de plataforma TMall: RMB 213.4 millones
• Ventas de plataforma JD.com: RMB 176.9 millones
• Ingresos totales de la plataforma de terceros: RMB 390.3 millones

Redes de redes sociales

Métricas de compromiso de las redes sociales para 2023:

Plataforma	Seguidores	Tasa de compromiso
Veloz	2.1 millones	4.7%
Weibo	1.6 millones	3.9%

Portales de consulta de telemedicina

Consultas de telemedicina en 2023:

• Consultas totales: 4.2 millones
• Duración de consulta promedio: 12.5 minutos
• Ingresos de la telemedicina: RMB 156.7 millones

111, Inc. (YI) - Modelo de negocio: segmentos de clientes

Consumidores de atención médica urbana

111, Inc. se dirige a las poblaciones urbanas con 42.6 millones de clientes potenciales en ciudades chinas de nivel 1 y nivel 2 a partir de 2023.

Segmento demográfico	Cobertura de la población	Gasto promedio de atención médica
Residentes urbanos de 25 a 45 años	23.4 millones	¥ 3,280 per cápita anualmente
Profesionales urbanos	18.2 millones	¥ 4,500 per cápita anualmente

Pacientes más jóvenes expertos en digital

Penetración de la plataforma de salud digital entre 18-35 Grupos de edad: 67.3% a partir del cuarto trimestre de 2023.

• Usuarios de la aplicación de salud móvil: 52.1 millones
• Usuarios de prescripción en línea: 18.6 millones
• Usuarios de consulta de telemedicina: 12.4 millones

Pacientes de manejo de enfermedades crónicas

El segmento de pacientes con enfermedad crónica representa el 31.5% del mercado total direccionable.

Condición crónica	Población de pacientes	Gasto de gestión anual
Diabetes	14.2 millones	¥ 2,780 por paciente
Hipertensión	22.6 millones	¥ 1,950 por paciente

Individuos conscientes de la salud

Bienestar y tamaño preventivo del mercado de la salud: ¥ 486 mil millones en 2023.

• Usuarios de suplementos nutricionales: 36.7 millones
• Participantes regulares de detección de salud: 24.3 millones
• Propietarios de dispositivos de seguimiento de fitness: 41.5 millones

Programas de beneficios de atención médica corporativa

Valor del segmento del mercado de la salud corporativa: ¥ 128.4 mil millones en 2023.

Tamaño de la empresa	Número de clientes corporativos	Gasto promedio de beneficios de atención médica anual
Grandes empresas (más de 1000 empleados)	3,280	¥ 2.1 millones
Enterprises medianos (200-999 empleados)	8,750	¥620,000

111, Inc. (YI) - Modelo de negocio: Estructura de costos

Mantenimiento de la infraestructura tecnológica

Los costos anuales de mantenimiento de la infraestructura tecnológica para 111, Inc. fueron de $ 3.2 millones en 2023, lo que representa el 5,4% de los gastos operativos totales.

Categoría de costos tecnológicos	Gasto anual ($)
Servicios en la nube	1,450,000
Sistemas de seguridad de TI	680,000
Licencia de software	520,000
Mantenimiento de hardware	550,000

Gestión de inventario farmacéutico

Los gastos de gestión de inventario farmacéutico total en 2023 alcanzaron los $ 12.7 millones.

• Costos de almacenamiento: $ 4.3 millones
• Sistemas de seguimiento de inventario: $ 1.2 millones
• Almacenamiento controlado por temperatura: $ 2.8 millones
• Seguro de inventario: $ 1.5 millones
• Software de gestión de inventario: $ 900,000

Desarrollo de plataforma digital

Los gastos de desarrollo de la plataforma digital totalizaron $ 5.6 millones en 2023.

Categoría de desarrollo	Gasto ($)
Ingeniería de software	3,200,000
Diseño de ui/ui	1,100,000
Desarrollo de aplicaciones móviles	850,000
Mantenimiento de la plataforma	450,000

Marketing y adquisición de clientes

Los gastos de marketing para 2023 fueron de $ 8.9 millones, con costos de adquisición de clientes de $ 42 por cliente nuevo.

• Publicidad digital: $ 3.6 millones
• Marketing en redes sociales: $ 1.5 millones
• Marketing de contenido: $ 1.2 millones
• Campañas promocionales: $ 1.8 millones
• Programas de retención de clientes: $ 800,000

Gastos de logística y distribución

Los costos totales de logística y distribución en 2023 ascendieron a $ 17.3 millones.

Categoría de logística	Gasto anual ($)
Transporte	7,200,000
Almacenamiento	5,600,000
Embalaje	2,300,000
Entrega de última milla	2,200,000

111, Inc. (YI) - Modelo de negocio: flujos de ingresos

Ventas farmacéuticas en línea

2023 Ingresos de ventas farmacéuticas en línea: $ 87.3 millones

Categoría de productos	Ingresos anuales	Porcentaje de ventas
Medicamentos recetados	$ 52.4 millones	60%
Drogas de venta libre	$ 34.9 millones	40%

Tarifas de consulta de salud digital

2023 Ingresos de consulta digital: $ 15.6 millones

• Tarifa de consulta promedio: $ 45 por sesión
• Consultas totales realizadas: 347,000
• Especialidades cubiertas: 12 disciplinas médicas

Comisiones de productos de salud

2023 Ingresos de la Comisión: $ 22.1 millones

Tipo de producto	Tarifa de comisión	Comisión total
Dispositivos médicos	12%	$ 9.3 millones
Suplementos para la salud	8%	$ 12.8 millones

Servicios de análisis de datos

2023 Ingresos de análisis de datos: $ 6.2 millones

• Instituciones de atención médica atendida: 87
• Valor promedio del contrato: $ 71,000

Paquetes de salud basados ​​en suscripción

2023 Ingresos de suscripción: $ 19.5 millones

Nivel de suscripción	Precio mensual	Suscriptores totales
Salud básica	$29	42,000
Salud premium	$79	18,500

111, Inc. (YI) - Canvas Business Model: Value Propositions

You're looking at the core benefits 111, Inc. (YI) delivers across its integrated online and offline healthcare platform as of late 2025. The numbers show a company focused on driving efficiency for its partners while scaling access for patients, even while navigating a tough macro environment.

One-stop, efficient sourcing for pharmacies (1 Drug Mall)

The 1 Drug Mall platform serves as the online wholesale pharmacy, acting as a one-stop shop for offline pharmacies to source products. This B2B focus is where a majority of 111, Inc. (YI)'s revenue is derived. The operational backbone supporting this value proposition saw tangible improvements in the second quarter of 2025.

The company expanded its fulfillment centers to 19 locations under the 'MANTIANXING' supply chain project by Q2 2025. This physical network supports a service promise: delivery to over 300 major cities within 24 hours, with national coverage guaranteed within 72 hours. That speed and reliability is a direct value-add for pharmacy partners.

Here are the recent partnership engagement metrics:

Metric	Period Ending June 30, 2025 (Q2 2025)	Year-over-Year Change
Sales Revenue from Marketing Promotional Products	Data not explicitly stated as absolute value	53.6% Increase
Customer Count (for Marketing Promotional Products)	Data not explicitly stated as absolute value	19.0% Increase
Total Operating Expenses as % of Net Revenues	5.8%	Decreased by 20 basis points

Increased patient access to cost-effective, reliable medicine

111, Inc. (YI) connects millions of consumers to pharmaceutical products and healthcare services through its 1 Pharmacy retail platform and its offline virtual pharmacy network. The scale of the business in 2025 reflects this access push. For the last twelve months ending June 30, 2025, the Trailing Twelve Months (TTM) revenue reached $1.97 Billion USD, which equates to approximately CNY14.18 billion. Still, you have to note that net revenues for Q2 2025 actually decreased by 6.4% compared to the same quarter last year, showing the pressure in the current market.

For the first quarter of 2025, net revenues were reported as RMB3.5 billion, or about US$486.3 million. The company managed to maintain positive operating cash flow in the first half of 2025, which is a key indicator of financial discipline supporting ongoing operations.

• Q1 2025 Net Cash from Operating Activities: RMB112.6 million (US$15.5 million).
• Q1 2025 Total Operating Expenses: RMB195.0 million (US$26.9 million).
• Q2 2025 Total Operating Expenses: RMB185.3 million (US$25.9 million).

Digital empowerment for upstream partners (pharmaceutical companies)

This value proposition centers on providing an omni-channel drug commercialization platform to strategic partners. This isn't just about moving boxes; it's about providing digital services that help manufacturers manage products effectively. The success here is clearly visible in the year-over-year growth metrics from Q2 2025.

The company offers services like digital marketing, patient education, data analytics, and pricing monitoring to these partners. The market is responding to this digital push, as evidenced by the growth in associated revenue streams. It's defintely a sign that partners are using the digital tools to reach consumers.

• Sales revenue from marketing promotional products saw a year-over-year increase of 53.6% in Q2 2025.
• The associated customer count for these services grew by 19.0% year-over-year in Q2 2025.

Convenient, remote healthcare via online consultation

Through its internet hospital, 1 Clinic, 111, Inc. (YI) delivers convenient, cost-effective online consultation and electronic prescription services directly to consumers. While specific consultation volume numbers aren't public, the platform's contribution to the company's operational stability is noted. The company achieved sustained operational profitability in Q1 2025.

The bottom-line results from the service segment show the focus on efficiency is translating into tangible, albeit small, operational gains. For instance, Non-GAAP income from operations was RMB4.3 million (approximately US$0.6 million) in Q1 2025, improving to RMB3.0 million (US$0.4 million) in Q2 2025, despite the net revenue dip that quarter.

If onboarding takes 14+ days, churn risk rises, but the digital nature of 1 Clinic inherently reduces physical friction for the patient.

111, Inc. (YI) - Canvas Business Model: Customer Relationships

You're looking at how 111, Inc. (YI) manages its connections with customers, which splits between high-volume digital interactions and dedicated partner support. The sheer scale of transactions dictates much of this structure.

Automated, high-volume transactional sales (B2B and B2C)

The foundation of volume is the platform's transactional throughput. For the first quarter of 2025, net revenues were reported at RMB 3.5 billion (US$486.3 million). This revenue base is supported by the massive scale of the underlying B2B and B2C transactions flowing through the system. To give you a sense of the recent trend, net revenues for the second quarter of 2025 showed a year-over-year decrease of 6.4%. The operational efficiency required to handle this volume is evident in the cost control measures, with total operating expenses in Q1 2025 being RMB 195.0 million (US$26.9 million).

The infrastructure supporting these transactions is constantly being scaled. As of the second quarter of 2025, strategic initiatives like the 'MANTIANXING' supply chain project expanded fulfillment centers to 19 locations.

Metric Category	Data Point (Period)	Value
Q1 2025 Net Revenues	Q1 2025	RMB 3.5 billion
Q2 2025 YoY Net Revenue Change	Q2 2025	-6.4%
Q1 2025 Selling and Marketing Expenses	Q1 2025	RMB 67.9 million
Fulfillment Center Count	Q2 2025	19 locations

Dedicated sales and service teams for strategic B2B partners

For the larger, more complex B2B relationships, 111, Inc. (YI) moves away from pure automation. The company provides an omni-channel drug commercialization platform to its strategic partners. While the exact size of the dedicated sales team isn't public, the financial commitment to marketing and engagement suggests significant human capital allocation here. For instance, selling and marketing expenses in Q1 2025 were RMB 67.9 million (US$9.4 million). This spend supports the high-touch engagement needed for these key accounts.

Digital marketing and patient education services for partners

A core offering to these strategic B2B partners includes services like digital marketing and patient education. The focus on digital promotion is reflected in the growth seen in related revenue streams. Sales revenue from marketing promotional products saw a substantial increase of 53.6% year-over-year in the second quarter of 2025. This indicates that the digital services component of the customer relationship is a significant growth driver.

Self-service platforms for ordering and inventory management

The digital infrastructure supports self-service for both consumers and pharmacy partners. For the consumer side, the platform's digital customer support system handles massive volume. Based on 2024 metrics, the system managed approximately 2.4 million online chat support interactions, 1.8 million mobile app support interactions, and 1.2 million email support interactions annually. The platform, 1 Medicine, acts as a one-stop shop for pharmacies to source products, which inherently includes self-service ordering and inventory visibility.

Here's a look at the scale of digital engagement these self-service channels manage:

• Online Chat Support Interactions (Annualized Estimate) - 2.4 million
• Mobile App Support Interactions (Annualized Estimate) - 1.8 million
• Email Support Interactions (Annualized Estimate) - 1.2 million
• Total Registered Users (As of Q3 2023, providing context for scale) - 4.2 million

The company's commitment to technology is also underscored by its intellectual property, having acquired four new patents recently, bringing the total to 28 as of August 2024. That's a lot of proprietary tech helping things run smoothly.

Finance: draft 13-week cash view by Friday.

111, Inc. (YI) - Canvas Business Model: Channels

The Channels component of 111, Inc. (YI) is defined by an integrated online and offline ecosystem designed to connect patients with drugs and healthcare services across China. This structure is segmented into B2C and B2B operations, supported by a significant physical logistics footprint.

The company's Q2 2025 net revenues were reported at 3.2 billion yuan. For the last twelve months ending June 30, 2025, total revenue reached approximately CNY 14.18 billion.

The company maintains operational profitability and positive operating cash flow for the first half of 2025.

Online B2B wholesale platform (1 Drug Mall)

The 1 Drug Mall functions as the online wholesale pharmacy, serving as a one-stop shop for other pharmacies to source pharmaceutical products. This platform is a core part of the company's B2B segment. Sales revenue from marketing products saw a surge of 53.6% in Q2 2025.

Online B2C retail pharmacy (1 Drugstore)

The 1 Drugstore, also referred to as 1 Pharmacy, is the online retail pharmacy platform, providing pharmaceutical and other health and wellness products directly to consumers. This channel falls under the B2C operating segment. Net revenues for Q1 2025 were RMB 3.5 billion (US$486.3 million).

Internet hospital platform (1 Clinic)

The 1 Clinic platform delivers online healthcare services, including cost-effective online consultation, electronic prescription services, and patient management services to consumers.

Offline virtual pharmacy network (last-mile fulfillment)

111, Inc. enables offline pharmacies to enhance customer service through cloud-based services, leveraging its virtual pharmacy network. The company states it has the largest virtual pharmacy network in China. Strategic initiatives, including the 'MANTIANXING' supply chain project, have resulted in 19 digital order fulfillment centers established to date. This network is capable of covering over 890 counties and cities nationwide within 24 hours.

Here's a quick look at the segment and infrastructure scale as of the first half of 2025:

Channel/Segment Component	Latest Reported Metric	Value/Amount	Reporting Period/Date
B2C Segment (Includes 1 Drugstore)	Net Revenues (Q1)	RMB 3.5 billion (US$486.3 million)	Q1 2025
B2B Segment (Includes 1 Drug Mall)	Sales Revenue from Marketing Products Growth	53.6% increase	Q2 2025
1 Clinic (Internet Hospital)	Non-GAAP Income from Operations	RMB 4.3 million (US$0.6 million)	Q1 2025
Offline Fulfillment Network	Number of Digital Order Fulfillment Centers	19 locations	Q2 2025
Overall Operations	Net Cash from Operating Activities	RMB 112.6 million (US$15.5 million)	H1 2025

The company's omni-channel support for strategic partners includes services such as digital marketing, patient education, data analytics, and pricing monitoring.

The company utilizes an AI order entry system within its supply chain, which improved document generation efficiency by over 60%. AI was also used for new product introductions, improving efficiency by 83%.

You can see the focus is on digital efficiency driving the physical fulfillment.

• Online B2C platform: 1 Drugstore/1 Pharmacy
• Online B2B platform: 1 Drug Mall
• Online Healthcare: 1 Clinic
• Offline Reach: Largest virtual pharmacy network in China

111, Inc. (YI) - Canvas Business Model: Customer Segments

You're looking at the core of 111, Inc. (YI)'s strategy, which is built on a dual-sided platform serving both businesses and individual patients. Honestly, their success hinges on how well they integrate these groups through their digital ecosystem.

The company operates through two primary segments: B2C, which is revenue from individual consumers, and B2B, which covers revenue from corporate customers, including pharmacies and manufacturers. To be fair, the search results indicate they derive a majority of their revenue from the B2B segment.

Here is a breakdown of the key customer groups they serve and the latest operational statistics we have from their mid-2025 reporting:

• Small to medium-sized independent pharmacies (primary B2B focus): These partners use the 1 Drug Mall platform to source products.
• Pharmaceutical manufacturers (upstream partners): They receive omni-channel support, including digital marketing and data analytics.
• Individual consumers seeking medicine and healthcare services (B2C): They are served via 1 Pharmacy (online retail) and 1 Clinic (internet hospital).
• Chain drug stores and other corporate customers: This group is part of the B2B revenue stream.

The growth in the B2B side, which digitally empowers pharmacies, is showing real traction. For example, in the second quarter of 2025, sales revenue from marketing promotional products, a service aimed at these partners, increased by a staggering 53.6% year-over-year. The customer count for this service also rose by 19.0% year-over-year in Q2 2025.

We can map the scale of their operations and the focus on these segments using the financial data from the first half of 2025. The Trailing Twelve Months (TTM) revenue for 2025 reached approximately $1.97 Billion USD.

Customer Segment Focus Area	Key Metric/Activity	Latest Reported Figure (2025)
Small to Medium-Sized Pharmacies (B2B)	Marketing Promotional Products Customer Count Growth (YoY)	19.0% increase in Q2 2025
Pharmaceutical Manufacturers (Upstream Partners)	Marketing Promotional Products Sales Revenue Growth (YoY)	53.6% increase in Q2 2025
Chain Drug Stores (B2B Sub-segment)	General Agency Anti-Infection Drug Monthly Sales Volume Growth	Rapidly increased to over seven times launch volume since Q1 2025
Individual Consumers (B2C)	Q1 2025 Net Revenues (Total Company)	RMB3.5 billion (about US$486.3 million)
Overall Platform Scale	TTM Revenue (Ending mid-2025)	$1.97 Billion USD

The B2C side is about direct access for millions of consumers through 1 Pharmacy and 1 Clinic. For the upstream partners, which include pharmaceutical manufacturers, the value proposition is digital empowerment, evidenced by the strong growth in marketing-related sales. The company is defintely using its digital tools to drive engagement across its entire partner base.

If onboarding for new pharmacy partners takes longer than expected, churn risk rises. Finance: draft 13-week cash view by Friday.

111, Inc. (YI) - Canvas Business Model: Cost Structure

You're looking at the hard numbers for 111, Inc. (YI)'s cost base as of the second quarter of 2025. It's all about the direct costs of goods and the operational spend to move them.

Cost Component	Q2 2025 Amount (RMB)	Q2 2025 Amount (US$)	Year-over-Year Context
Cost of products sold	RMB 3.0 billion	US$421.6 million	Decreased by 6.1% from Q2 2024.
Fulfillment expenses	RMB 90.2 million	US$12.6 million	Increased by 2.4% from Q2 2024.
Selling and marketing expenses	RMB 66.2 million	US$9.2 million	Fell 17.7% from Q2 2024 (RMB 80.4 million).
Technology expenses	RMB 14.9 million	US$2.1 million	Decreased by 19.0% from Q2 2024 (RMB 18.4 million).

The infrastructure supporting this is scaling up. That's a key part of the capital outlay you need to track.

• Fulfillment center network reached 19 locations nationwide by the end of Q2 2025.
• The company is focused on AI innovation and digitalization for supply chain optimization.

For technology development and maintenance, which covers things like AI and cloud usage, the direct expense line shows a clear trend of cost reduction in the quarter.

• Technology expenses were RMB 14.9 million (US$2.1 million) in Q2 2025.
• This represented a 19.0% year-over-year reduction.

Selling and marketing shows a significant pullback in spend, which is worth noting against the revenue performance.

• Selling and marketing expenses were RMB 66.2 million (US$9.2 million) in Q2 2025.
• That's a 17.7% drop compared to the same period last year.

Overall operating expenses as a percentage of net revenues improved, coming in at 5.8% for Q2 2025, down from 6.0% in Q2 2024. That's efficiency in action.

111, Inc. (YI) - Canvas Business Model: Revenue Streams

The revenue generation for 111, Inc. (YI) is anchored in its tech-enabled healthcare platform, primarily driven by the distribution of pharmaceutical products. Sales of pharmaceutical products via the B2B segment constitute the majority of the total revenue, flowing through its online wholesale pharmacy, 1 Drug Mall, which serves as a one-stop shop for offline pharmacies to source products. This wholesale channel supports the extensive virtual pharmacy network across China.

The B2C segment also contributes significantly, providing millions of consumers with direct access to pharmaceutical products through its online retail pharmacy, 1 Drugstore, and its offline virtual pharmacy network. The company's overall financial performance for the second quarter of 2025 showed net revenues of 3.2 billion yuan (RMB), though this represented a decrease of 6.4% compared to the same period last year.

A notable growth area is revenue from marketing promotional products. This stream saw a substantial year-over-year increase of 53.6% in Q2 2025. This success is tied to the digital marketing platform empowering upstream partners, and the customer count supporting this segment grew by 19.0% YoY in the same quarter.

Service fees from online consultation and e-prescription are generated through the internet hospital, 1 Clinic. This service provides consumers with cost-effective and convenient access to healthcare services.

Here's a quick look at some key financial metrics around the revenue base as of mid-2025:

Metric	Value	Period/Date
Trailing Twelve Months (TTM) Revenue	$1.97 Billion USD	As of June 30, 2025
Q2 2025 Net Revenues	3.2 Billion RMB	Q2 2025
Marketing Promotional Products Sales Revenue Growth	Up 53.6%	YoY in Q2 2025
Operating Expenses as % of Net Revenues	5.8%	Q2 2025

The revenue derived from 1 Clinic services is built upon specific digital offerings:

• Online consultation
• Electronic prescription service
• Patient management service